Ziconotide

Therapeutic

Ziconotide is indicated for the management of severe chronic pain in patients refractory to other treatments, and for whom intrathecal therapy is warranted

Structural features

SMILES

C[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N3)CO)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN

Sequence

C(1)KGKGAKC(2)SRLMYDC(3)C(1)TGSC(2)RSGKC(3)-NH2

Molar mass

2639.14 g/mol

Constitutional members:

25

Natural amino acids

25

D-Amino acids

0

N-terminus

H

C-terminus

NH2

Cyclic

yes

Members/cycle

multicyclic

Bond to form cycle

3 side chain-to-side chain (disulfide)

Lipidation

no

Glycosylation

no

Route of administration

IT

Terminal half-life

4.6 hours

Protein binding

0.5

Absorption and Bioavailability

-

References